| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |